Gain Therapeutics, Inc.
NASDAQ:GANX · NASDAQ Global Market
+$0.06 today
Vol 0.50M · Avg 0.64M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-108.6%
avg -18.8%
ROIC
-95.0%
avg 108.0%
ROA
-88.4%
avg -123.8%
Analysis
ROA is currently the strongest return metric at -88.4% versus its period average of -123.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gene Mack | President, Chief Executive Officer & Director | $664,320.00 | — | 52 | $200,000.00 | 0.47% |
Gianluca Fuggetta | Senior Vice President of Finance & Principal Financial Officer | $263,074.00 | — | 37 | $50,000.00 | 0.12% |
Khalid Islam | Chairman & Founder | $75,000.00 | — | 71 | $15,000.00 | 0.04% |
Joanne Taylor | Senior Vice President of Research | — | — | — | — | — |
Jonas Hannestad | Chief Medical Officer | — | — | — | — | — |
Terenzio Ignoni | Senior Vice President of Technical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +50.3% | +135.9% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +50.3% over three years. Forward estimates point to Revenue at +135.9% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$138.36M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.82M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Adicet Bio, Inc.
NASDAQ:ACET
$75.91M
XBiotech Inc.
NASDAQ:XBIT
$71.65M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.81M
Nutriband Inc.
NTRB
$38.41M
CervoMed Inc.
CRVO
$37.87M
Lite Strategy, Inc.
LITS
$29.34M
Who manages GANX?
Gain Therapeutics, Inc. (GANX) lists 6 active executives. The top listed executive is Joanne Taylor, Senior Vice President of Research.
Are GANX insiders buying or selling?
Recent insider activity shows net buying of $32.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.